ClinicalTrials.gg
CompletedNCT00356096Updated May 21, 2012

Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances

A Phase 4 interventional study of pramipexole in Restless Legs Syndrome and Depression, sponsored by Boehringer Ingelheim. Completed at 54 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2012-05-21.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
404
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
Largest of 17
404 · median 154
Started
2006
with 4 others
Phase 4
8 of 17
none open now
Registered
9th of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one has the largest enrollment, is one of 5 that started in 2006, is one of 8 in phase 4, and was the 9th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

The primary objective of this study is to determine the efficacy of pramipexole 0.125 mg to 0.75 mg daily versus placebo on RLS symptoms and on associated mood disturbances and depressive symptoms, after 12 weeks of treatment

03

Conditions studied

  • Restless Legs Syndrome
  • Depression
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written consistent with ICH-GCP and local IRB/IEC requirements obtained prior to any study procedures being performed and the ability and willingness to comply with study treatment regimen and to attend study assessments.
  2. Male or female out-patients aged 18-80 years.
  3. Diagnosis of idiopathic RLS according to the clinical RLS criteria of the IRLSSG [P03-03355]. All four criteria must be present to fulfil the diagnosis of RLS:

    An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs. (Sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs) The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night. (When symptoms are very severe, the worsening at night may not be noticeable but must have been previously present).

  4. RLS symptoms present at least 2 to 3 days per week during the last 3 months prior to baseline (Visit 2).
  5. In addition all of the following must be demonstrated at Visit 2 (baseline):

IRLS total score >15 A score of >=2 for item 10 of the IRLS rating scale

Exclusion criteria

Exclusion Criteria:

  1. Women of who do not use an adequate method of
  2. Any women of child-bearing potential not having negative pregnancy test at screening
  3. Breastfeeding women
  4. Concomitant or previous pharmacologic therapy for RLS
  5. All treatment less than 14 days before baseline or concomitant treatment with medication or dietary supplements, which could significantly influence RLS symptoms
  6. Withdrawal symptoms of any medication must not be present at baseline
  7. Previous pramipexole non-responders in other indications than RLS.
  8. to pramipexole or any other component of the product
  9. Diagnosis of diabetes mellitus requiring insulin
  10. Any of the following laboratory results at screening: abnormalities at the investigatos discretion; below lower limit of normal
  11. Clinically significant renal disease at screening
  12. Clinically significant hepatic disease at screening
  13. Serum ferritin \<10 ng/mL at screening.
  14. History of/or malignant melanoma.
  15. History of/or clinically significant vision abnormalities
  16. History of/or any other sleep disorder
  17. History of/or major depressive disorder or any psychotic disorder, mental disorders or any present Axis I psychiatric disorder according to DSM IV requiring any medical therapy, or BDI-II total score >28
  18. History of/or clinical signs of suicidal behaviour, suicide ideation or acute suicidal tendency according to the investigators opinion
  19. History of/or alcohol abuse or drug addiction within the last 2 years before screening
  20. Patients on a shift-work-schedule or otherwise unable to follow a regular sleep-wake cycle
  21. Participation in an investigational drug study within one month prior to the start of this study
  22. Patients with any clinically significant conditions that in the opinion of the investigator
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Intervention model
Parallel assignment
Enrollment
404 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. The primary endpoint is the change from baseline after 12 weeks of treatment in: IRLS total score, IRLS item 10 score and BDI-II total score

    Time frame: 12 weeks

Secondary outcomes

  1. The following endpoints will be analysed: CGI-I, IRLS and BDI-II responder rate, VAS score for pain in limbs, RLS-6 item scores, HADS-A score, RLS-QoL score, PGI responder rate, Adverse events profile, Systolic and diastolic blood pressure, Pulse rate

    Time frame: 12 weeks

07

Study locations

54 sites
  • 248.604.35801 Boehringer Ingelheim Investigational Site
    Espoo, Finland
  • 248.604.35805 Boehringer Ingelheim Investigational Site
    Helsinki, Finland
  • 248.604.35803 Boehringer Ingelheim Investigational Site
    Lahti, Finland
  • 248.604.35802 Boehringer Ingelheim Investigational Site
    Oulu, Finland
  • 248.604.3301A HOP Le Vinatier,Psychiat,Bron
    Bron, France
  • 248.604.3304B Hôpital Roger Salengro
    Lille cedex, France
  • 248.604.3307A Cabinet Médical
    Montbrison, France
  • 248.604.3303A Hôpital Gui de Chauliac
    Montpellier cédex 5, France
  • 248.604.3303C Hôpital Gui de Chauliac
    Montpellier cédex 5, France
  • 248.604.3302A Hôpital Pitié Salpétrière
    Paris cédex 13, France
  • 248.604.3305B Hôpital du Haut Levêque
    Pessac cédex, France
  • 248.604.4903 Boehringer Ingelheim Investigational Site
    Berlin (Hellersdorf), Germany
  • 248.604.4902 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.604.4904 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.604.4905 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.604.4906 Boehringer Ingelheim Investigational Site
    Berlin, Germany
  • 248.604.4909 Boehringer Ingelheim Investigational Site
    Chemnitz, Germany
  • 248.604.4901 Boehringer Ingelheim Investigational Site
    Freiburg, Germany
  • 248.604.4907 Boehringer Ingelheim Investigational Site
    Kassel, Germany
  • 248.604.4910 Boehringer Ingelheim Investigational Site
    Leipzig, Germany
  • 248.604.4908 Boehringer Ingelheim Investigational Site
    Marburg, Germany
  • 248.604.4911 Boehringer Ingelheim Investigational Site
    München, Germany
  • 248.604.35305
    Carrigtwohill, Ireland
  • 248.604.35302 Boehringer Ingelheim Investigational Site
    Castledermot, Ireland
  • 248.604.3901 Università degli Studi di Bologna
    Bologna, Italy
  • 248.604.3905 Casa di Cura Villa Serena
    Città S. Angelo (PE), Italy
  • 248.604.3906 Clinica Psichiatrica
    Pisa, Italy
  • 248.604.3902 IRCCS San Raffaele
    Roma, Italy
  • 248.604.3909 IRCCS Fondazione "Salvatore Maugeri"
    Telese Terme (be), Italy
  • 248.604.3908 Azienda Sanitaria San Giovanni Battista
    Torino, Italy
  • 248.604.3904 IRCCS Oasi Maria SS
    Troina (Enna), Italy
  • 248.604.82001 Boehringer Ingelheim Investigational Site
    Daegu, Korea, Republic of
  • 248.604.82003 Boehringer Ingelheim Investigational Site
    Incheon, Korea, Republic of
  • 248.604.82002 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 248.604.82004 Boehringer Ingelheim Investigational Site
    Seoul, Korea, Republic of
  • 248.604.3401
    Madrid, Spain
  • 248.604.3403
    Madrid, Spain
  • 248.604.3405
    Madrid, Spain
  • 248.604.3407
    Oviedo, Spain
  • 248.604.3402
    San Cugat del Vallés (Barcelona), Spain
  • 248.604.3404 Hospital de Donostia
    San Sebastián, Spain
  • 248.604.4602 Boehringer Ingelheim Investigational Site
    Göteborg, Sweden
  • 248.604.4603 Boehringer Ingelheim Investigational Site
    Göteborg, Sweden
  • 248.604.4601 Boehringer Ingelheim Investigational Site
    Hedemora, Sweden
  • 248.604.4604 Boehringer Ingelheim Investigational Site
    Skövde, Sweden
  • 248.604.4606 Boehringer Ingelheim Investigational Site
    Stockholm, Sweden
  • 248.604.4605 Boehringer Ingelheim Investigational Site
    Örebro, Sweden
  • 248.604.44004 Boehringer Ingelheim Investigational Site
    Cambridge, United Kingdom
  • 248.604.44006 Boehringer Ingelheim Investigational Site
    Chorley, United Kingdom
  • 248.604.44001 Boehringer Ingelheim Investigational Site
    London, United Kingdom
  • 248.604.44007 Boehringer Ingelheim Investigational Site
    Manchester, United Kingdom
  • 248.604.44009 Boehringer Ingelheim Investigational Site
    Reading, United Kingdom
  • 248.604.44002 Boehringer Ingelheim Investigational Site
    Romford, United Kingdom
  • 248.604.44005 Boehringer Ingelheim Investigational Site
    West Green, Crawley, United Kingdom
08

References and documents

Publications

  • Hornyak M, Sohr M, Busse M; 604 and 615 Study Groups. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials. Sleep Med. 2011 Feb;12(2):186-9. doi: 10.1016/j.sleep.2010.11.007. Epub 2011 Jan 21. PubMed 21256799 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006 and a primary completion of Jun 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2006
First posted
Jul 25, 2006
Start
Jul 2006
Primary completionActual
Jun 2007
Last update
May 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00356096
First posted
Jul 25, 2006
Start date
Jul 2006
Primary completion
Jun 2007
Last update
May 21, 2012

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion